Group items tagged

The Lyon Diet Heart Study: \nde Lorgeril M, Renaud S, Mamelle N, Salen P, Martin JL, Monjaud I,\nGuidollet J, Touboul P, Delaye J.\nMediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease.\nLancet. 1994 Jun 11;343(89

de Lorgeril M, Salen P, Martin J-L, Monjaud I, Delaye J, Mamelle N:\nMediterranean diet, traditional risk factors and the rate of\ncardiovascular complications after myocardial infarction. Final report of the Lyon Diet Heart Study.\nCirculation 1999, Febr

Promotion of bone formation by fermented soybean (Natto) intake in premenopausal women.\nKatsuyama H, Ideguchi S, Fukunaga M, Fukunaga T, Saijoh K, Sunami S.\nJ Nutr Sci Vitaminol (Tokyo). 2004 Apr;50(2):114-20.\nPMID: 15242015

LYSAKER, Norway, April 11, 2008-An increased intake of vitamin K2 may reduce the risk of prostate cancer by 35 per cent, suggest results from the European Prospective Investigation into Cancer and Nutrition (EPIC). The findings, based on dietary intake from 11,319 men taking part in the EPIC Heidelberg cohort, are published in this month's issue of the American Journal of Clinical Nutrition.

Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico.\nLancet. 1999 Aug 7;354(9177):447-55. Erratum in: Lancet 2001 Feb 24;357(9256):642. Lancet. 2007 Jan 13;369(9556):106.\nPMID: 10465168

Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Pantuck AJ, Leppert JT, Zomorodian N, Aronson W, Hong J, Barnard RJ, Seeram N, Liker H, Wang H, Elashoff R, Heber D, Aviram M, Ignarro L, Belldegrun A. Clin Cancer Res. 2006 Jul 1;12(13):4018-26. PMID: 16818701

Effects of pistachios on cardiovascular disease risk factors and potential mechanisms of action: a dose-response study. Gebauer SK, West SG, Kay CD, Alaupovic P, Bagshaw D, Kris-Etherton PM. Am J Clin Nutr. 2008 Sep;88(3):651-9. PMID: 18779280

Combination immunotherapy of squamous cell carcinoma of the head and neck: a phase 2 trial. Barrera JL, Verastegui E, Meneses A, Zinser J, de la Garza J, Hadden JW. Arch Otolaryngol Head Neck Surg. 2000 Mar;126(3):345-51. PMID: 10722007

(SACRAMENTO, Calif.) - Osteoporosis affects many women and can cause painful, disabling and even life-threatening fractures. Researchers from the UC Davis Department of Internal Medicine are seeking a simple, inexpensive way to prevent the disease. Strontium citrate is a widely available, over-the-counter dietary supplement promoted to "improve bone health." Strontium is a natural element found in bone in all people. Strontium citrate is another form of strontium ranelate, a proven medication prescribed across Europe and Australia to treat and prevent osteoporosis and related fractures. Unlike pharmaceuticals, strontium citrate is not a prescribed medication and is inexpensive.

Conclusions/interpretation These results show that the previously demonstrated beneficial effects of these agents on complication-causing pathways in rodent models of diabetic complications also occur in humans with type 1 diabetes. Oral benfotiamine plus alpha-lipoic acid normalises complication-causing pathways in type 1 diabetes. Du X, Edelstein D, Brownlee M. Diabetologia. 2008 Oct;51(10):1930-2. Epub 2008 Jul 29. PMID: 18663426 DOI: 10.1007/s00125-008-1100-2

"Dr. Jodie Burton is the acting principal investigator (PI) of the dose-escalation trial of oral vitamin D3 with calcium supplementation in patients with multiple sclerosis with Dr. O'Connor. She started the trial as his fellow, while doing an additional 2 years of training in MS specifically after she received her neurology certification. She completed her fellowship training in 2007. Now she is staff doing clinical research and continuing with the vitamin D trial. As of August 2009, she will be Assistant Professor in Neurology in the Department of Clinical Neuroscience in Calgary and at the University of Calgary. She will be part of the MS team there with Dr. Luanne Metz and the MS group. Please scroll down for an abstract of the trial: A Phase I/II dose-escalation trial of oral vitamin D3 with calcium supplementation in patients with multiple sclerosis." Conclusions: High-dose VD3 (~10 000 IU/day, possibly higher) in MS is safe and tolerable, with evidence of clinical improvement.

Safety of vitamin D3 in adults with multiple sclerosis. Kimball SM, Ursell MR, O'Connor P, Vieth R. Am J Clin Nutr. 2007 Sep;86(3):645-51. PMID: 17823429 Conclusions: Patients' serum 25(OH)D concentrations reached twice the top of the physiologic range without eliciting hypercalcemia or hypercalciuria. The data support the feasibility of pharmacologic doses of vitamin D3 for clinical research, and they provide objective evidence that vitamin D intake beyond the current upper limit is safe by a large margin.